Evidence map›Paper›PMID 29137877›Full record

ArticleClinical genitourinary cancer2018

Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.

Joseph W Kim, Min Sun Shin, Youna Kang, Insoo Kang, Daniel P Petrylak

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Immunological effects of radiopharmaceutical therapy.Frontiers in nuclear medicine · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Advances in targeted alpha therapy for prostate cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joseph W KimDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT; Prostate and Urological Cancers Program, Yale Comprehensive Cancer Center, New Haven, CT. Electronic address: joseph.w.kim@yale.edu.
Min Sun ShinDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Youna KangDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Insoo KangDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Daniel P PetrylakDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT; Prostate and Urological Cancers Program, Yale Comprehensive Cancer Center, New Haven, CT.

Funding

Aging and IL-7-Mediated CD8+ T Cell SurvivalR56AG028069 · NIA · YALE UNIVERSITY · PI KANG, INSOO · 2015 to 2015
$416k
NIA NIH HHS R56 AG028069
6 · The paper itself

Abstract

backgroundRadium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown. PATIENTS AND

methodsFifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg. Concurrent use of prednisone ≤ 10 mg a day was allowed. Peripheral blood samples were collected before and 3 to 4 weeks after the first dose of Ra223 50 kBq/kg. Peripheral blood mononuclear cells were purified and analyzed for the phenotypic and functional characteristics of CD8

resultsOne Ra223 treatment did not result in significant change in the overall frequencies of CD8

conclusionOne Ra223 treatment is associated with a decreased mean frequency of programmed cell death protein 1-expressing effect memory CD8

Indexed as

Administration, IntravenousAgedAged, 80 and overBone NeoplasmsCD8-Positive T-LymphocytesHumansInterferon-gammaInterleukin-13MaleMiddle AgedPrednisoneProgrammed Cell Death 1 ReceptorProstatic Neoplasms, Castration-ResistantRadiumTreatment OutcomeTumor Necrosis Factor-alphaIFNG protein, humanIL13 protein, humanInterferon-gammaInterleukin-13PDCD1 protein, humanPrednisoneProgrammed Cell Death 1 ReceptorRadiumRadium-223TNF protein, humanTumor Necrosis Factor-alphaImmune effectPD-1RadioisotopeSurvivalXofigo

Identifiers

PMID29137877
PMCPMC5878980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.